Start-up get funding for microarray work

IncTank Ventures has put up $1 million in funding to back Cambridge, MA-based start-up Ligon Discovery. Ligon is hoping that its technology platform, Small-Molecule Microarrays (SMMs), will bring the power of microarrays to target screening. The technology was developed at Havard University and the Broad Institute, and allows for massively-parallel screening against protein targets of any function. Mass High Tech notes that the company was founded by Broad Institute and Havard members Patrick Kleyn, Angela Koehler and Benjamin Ebert, among others.

- here's the Mass High Tech brief

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.